Track record · closed signal

Hims & Hers Health, Inc. (HIMS) — closed signal from October 31, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 29, 2026.

Predicted vs. what happened

HIMS price · publication thesis → realized outcomesplit-adjusted
$45.68 Published $57.09 Target $29.87 Window close $48.34 Peak
$44.00 – $46.00Entry zone — fair-value band
$45.68Published — price the day we called it
$57.09Target — the price the thesis aimed for
$48.34Peak — highest point inside the window, not a realized return
$29.87Window close — end-of-window price, context only

What happened

Partial

Reached 23% of the predicted growth at its peak, without hitting the target.

Peak price
$48.34
peak on November 4, 2025 — not a realized return
Peak gain
+5.8%
peak, from the publication price
Window close
$29.87
end-of-window price, context only
Days to target
—
Window
October 31, 2025 – January 29, 2026

The thesis — published October 31, 2025

Predicted growth
+25%
over the measurement window
Target price
$57.09
the price the thesis aimed for
Entry zone
$44.00 – $46.00
the fair-value band we waited for
Price at publication
$45.68
published October 31, 2025
Confidence
60%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

HIMS has an important moment coming with its Nov 3 earnings report. Recent news shows customer counts are rising and the company is generating more free cash, which supports long-term value. A new investor lawsuit could also make the stock swing. Because the price has been weak, start small and add only if the day after earnings shows healthy demand. Over the next 0-3 months, clear guidance could lift the shares, but use discipline.

Primary drivers

  • Upcoming earnings could quickly change views and drive a sharp price move.
  • Rising customer counts and stronger free cash flow support growth today.
  • An investor lawsuit hangs over the stock and can add swings and uncertainty.
  • Recent weakness means wait for firm buying after earnings before adding more.

How it played out

HIMS: the target was not reached

Lyra published HIMS at $45.68 on 2025-10-31, with 25% expected growth over the short term. The thesis pointed to the Nov. 3 earnings report, rising customer counts, stronger free cash flow, an investor lawsuit that could add swings, and the need to see firm buying after earnings before adding more.

Inside the window, HIMS peaked at $48.34 on 2025-11-04, a 5.8% gain. It stayed below the $57.09 target and never reached it. By 2026-01-29, it ended at $29.87. The thesis did not play out according to the price result.

What happened during the window

On 2025-11-04, Investor's Business Daily reported that Hims & Hers had posted third-quarter revenue of $599 million and said it was in discussions with Novo Nordisk to sell Wegovy. MarketWatch also reported the talks on 2025-11-04 and said the company guided fourth-quarter revenue to $605 million to $625 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HIMS signals